Juliana de Brito Rangel1, Luiz Claudio Santos Thuler2, Jorge Francisco da Cunha Pinto3. 1. Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil. 2. Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil; Federal University of Rio de Janeiro State (UNIRIO), Rio de Janeiro, Brazil. Electronic address: lthuler@gmail.com. 3. Federal University of Rio de Janeiro State (UNIRIO), Rio de Janeiro, Brazil.
Abstract
OBJECTIVE: Several studies have shown a higher prevalence of hepatitis C virus (HCV) infection among patients with head and neck cancer (HNC) compared to the general population. In Brazil, the prevalence of HCV infection is considered low (1.38%). The aim of this study was to determine HCV prevalence and how this can modify outcomes of patients with HNC. STUDY DESIGN: Retrospective cohort. METHODS: Patients with a diagnosis of malignant neoplasm in the head and neck (HN) region and who had serology performed for HCV were included. Patients were classified into two groups: head and neck squamous cell carcinoma (HNSCC) and other head and neck malignant neoplasms (OHNMN). Descriptive statistics were performed for all variables of interest. Means were compared using ANOVA and proportions using chi-square tests. Survival data were compared by Kaplan-Meier curves and log-rank test. RESULTS: Global HCV prevalence in patients with HNC was 7.8%, reaching 12.8% in HNSCC and 3.4% in OHNMN (p = 0.003). There was a higher risk of developing a second primary neoplasm in HNSCC compared to OHNMN patients (20.6% versus 4.6%; p = 0.001). The mean survival was not different between HCV-positive and HCV-negative patients (6.0 years versus 6.6 years, respectively, p = 0.516). CONCLUSION: The prevalence of HCV infection was higher in HNC patients compared to the general Brazilian population. It seems reasonable to consider that HCV infection is associated with an increased risk of HNC, but HCV infection does not worsens the prognosis of HNC patients.
OBJECTIVE: Several studies have shown a higher prevalence of hepatitis C virus (HCV) infection among patients with head and neck cancer (HNC) compared to the general population. In Brazil, the prevalence of HCV infection is considered low (1.38%). The aim of this study was to determine HCV prevalence and how this can modify outcomes of patients with HNC. STUDY DESIGN: Retrospective cohort. METHODS:Patients with a diagnosis of malignant neoplasm in the head and neck (HN) region and who had serology performed for HCV were included. Patients were classified into two groups: head and neck squamous cell carcinoma (HNSCC) and other head and neck malignant neoplasms (OHNMN). Descriptive statistics were performed for all variables of interest. Means were compared using ANOVA and proportions using chi-square tests. Survival data were compared by Kaplan-Meier curves and log-rank test. RESULTS: Global HCV prevalence in patients with HNC was 7.8%, reaching 12.8% in HNSCC and 3.4% in OHNMN (p = 0.003). There was a higher risk of developing a second primary neoplasm in HNSCC compared to OHNMNpatients (20.6% versus 4.6%; p = 0.001). The mean survival was not different between HCV-positive and HCV-negative patients (6.0 years versus 6.6 years, respectively, p = 0.516). CONCLUSION: The prevalence of HCV infection was higher in HNC patients compared to the general Brazilian population. It seems reasonable to consider that HCV infection is associated with an increased risk of HNC, but HCV infection does not worsens the prognosis of HNC patients.
Authors: Harrys A Torres; Anna S Lok; Maria E Suarez-Almazor; Carla L Warneke; Ahmed Kaseb; Ethan Miller; Erich M Sturgis; Jessica T Foreman; Georgios Angelidakis; Sairah Ahmed; Alessandra Ferrajoli; Felipe Samaniego; Ernest T Hawk; Jessica P Hwang Journal: Support Care Cancer Date: 2020-04-20 Impact factor: 3.603
Authors: Neil D Christensen; Kun-Ming Chen; Jiafen Hu; Douglas B Stairs; Yuan-Wan Sun; Cesar Aliaga; Karla K Balogh; Hannah Atkins; Debra Shearer; Jingwei Li; Sarah A Brendle; Krishne Gowda; Shantu Amin; Vonn Walter; Raphael Viscidi; Karam El-Bayoumy Journal: Chem Biol Interact Date: 2020-11-10 Impact factor: 5.168